Business Wire

SLATE-ASSET-MANAGEMENT

22.7.2022 08:02:07 CEST | Business Wire | Press release

Share
Slate Asset Management Acquires Majority Stake in Germany-Based Electric Vehicle Charging Planner and Developer, amperio GmbH

Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced that it has acquired a majority stake in amperio GmbH (“amperio”), a specialist planner and operator of electric vehicle (“EV”) charging infrastructure in Germany.

Amperio is a leading planner and operator of EV charging stations in the highly-fragmented EV charging market in Germany. Since 2012, amperio has been supporting companies, cities, and communities in developing tailored charging concepts, installing charging stations, and providing backend management services for charging stations. To date, amperio has installed over 1,800 intelligent charging points. Amperio maintains, operates, and executes the billing for over 300 of these charging points on behalf of its customers.

As part of the transaction, Slate created Slate Mobility GmbH & Co. KG (“Slate Mobility”), an entity that will finance and own EV charging equipment for Slate and potential third parties and receive management services from amperio. Slate’s portfolio of over 225 grocery properties across Germany and deep network of relationships with tenants focused on environmental sustainability will create a pipeline of opportunities to accelerate amperio’s growth.

Amperio, together with Move About Groups subsidiary mobileeee GmbH (“mobileeee”) and the City of Ludwigshafen in Germany, are implementing a project for station-based public e-carsharing. The project includes the build-up of 27 stations with mobileeee charging infrastructure as well as publicly accessible charging infrastructure. The City Ludwigshafen initiated this concept with the aim of reducing local emissions in the City and its districts.

“To achieve the German government’s target of having at least 15 million electric cars on the roads by 2030 will require significant investment in EV charging points throughout the country,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Amperio is offering a unique, customizable national product to help meet this demand, backed by a team with a proven track record of experience developing charging infrastructure for cities, communities, and businesses. We are excited to partner with amperio to enhance the sustainability infrastructure of our own properties and improve access to efficient charging points all across Germany.”

“Our partnership with Slate presents an exciting opportunity to scale our business and provide seamless and sustainable mobility solutions that are so urgently needed to protect the climate,” added Oliver P. Kaul, Managing Director of amperio. “Our environment has given us the assignment to create zero-emission mobility. Slate has offered us its properties and the funding to accelerate that mission, which amperio embarked on 10 years ago. Together, we strive to achieve our goal of making clean EV charging technology and services widely available.”

Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. Slate’s most recent impact infrastructure investment was a commitment to Eider VF Limited, a UK-based vertical farming business sustainably growing leafy produce to be sold to the UK mass market.

About Slate Asset Management

Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities.

Visit slateam.com to learn more.

About amperio

amperio GmbH is a specialist planner for charging infrastructure based in Cologne. Since 2012, amperio has been supporting companies, cities and municipalities in developing individual charging concepts, installing charging stations and billing charging processes. In doing so, amperio relies on a holistic service that leaves no customer wishes unfulfilled. This includes location analysis, profitability analysis, business model analysis, technical consulting, backend service (monitoring and billing), the operation of charging points, and energy management and subsidy consulting. In addition, amperio offers two charging infrastructure concepts developed in-house with its CHARGE2GO and Mitarbeiter-Strom products. The company has already installed over 1,800 charging points for customers such as Globus, DKB, Groupe PSA, the city of Düren, Volvo, the city of Bad Ems and the MNT Group.

amperio GmbH is part of Slate Asset Management, a global alternative investment platform, which holds a majority stake in amperio GmbH.

Visit amperio.eu to learn more.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye